Table 1.
Characterizations of breast cancer patients on endocrine treatments.
| Variable | Aromatase inhibitors | Aromatase inhibitors with GnRH agonists or antagonists | Tamoxifen | Tamoxifen with GnRH agonists or antagonists |
|---|---|---|---|---|
| N | 6634 | 253 | 2887 | 132 |
| Mean (SD) age | 68.2 (11.97) | 44.86 (6.27) | 54.69 (12.19) | 42.94 (6.94) |
| Median (IQR) age | 68 (59–77) | 46 (40–50) | 52 (47–62) | 44 (38.75–48) |
| Median prior history (years) | 16.06 (11.1–18.85) | 14.47 (6.65–18.23) | 15.15 (9.48–17.95) | 13.86 (6.66–17.46) |
| Mean Charlson Index | 0 | 0 | 0 | 0 |
| Median Charlson Index | 0 | 0 | 0 | 0 |
| N male | 0 | 0 | 0 | 0 |
| N Female | 6634 | 253 | 2887 | 132 |
| % Female | 100 | 100 | 100 | 100 |
| Comorbidities [n (%)] | ||||
| Atrial fibrillation | 390 (5.88) | 0 (0) | 40 (1.39) | 0 (0) |
| Cerebrovascular disease | 306 (4.61) | <5 (~1) | 35 (1.21) | <5 (~1) |
| Chronic liver disease | 40 (0.6) | <5 (~0) | 8 (0.28) | 0 (0) |
| Chronic obstructive lung disease | 348 (5.25) | <5 (~0) | 80 (2.77) | 0 (0) |
| Coronary arteriosclerosis | 38 (0.57) | 0 (0) | 13 (0.45) | 0 (0) |
| Crohn’s disease | 18 (0.27) | 0 (0) | 8 (0.28) | 0 (0) |
| Dementia | 127 (1.91) | 0 (0) | 10 (0.35) | 0 (0) |
| Depressive disorder | 1195 (18.01) | 58 (22.92) | 540 (18.7) | 29 (21.97) |
| Diabetes mellitus | 731 (11.02) | 11 (4.35) | 127 (4.4) | <5 (~3) |
| Helicobacter pylori infection | 20 (0.3) | <5 (~0) | <5 (~0) | 0 (0) |
| Heart disease | 925 (13.94) | 5 (1.98) | 172 (5.96) | <5 (~1) |
| Heart failure | 129 (1.94) | 0 (0) | 14 (0.48) | 0 (0) |
| Hepatitis C | <5 (~0) | 0 (0) | <5 (~1) | 0 (0) |
| HIV | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
| Hyperlipidaemia | 615 (9.27) | <5 (~1) | 109 (3.78) | <5 (~1) |
| Hypertension | 1835 (27.66) | 26 (10.28) | 442 (15.31) | 10 (7.58) |
| Ischaemic heart disease | 324 (4.88) | <5 (~1) | 62 (2.15) | 0 (0) |
| Lesion liver | 87 (1.31) | 9 (3.56) | 16 (0.55) | 0 (0) |
| Obesity | 277 (4.18) | 6 (2.37) | 78 (2.7) | <5 (~3) |
| Osteoarthritis | 1532 (23.09) | <5 (~1) | 328 (11.36) | <5 (~2) |
| Peripheral vascular disease | 81 (1.22) | 0 (0) | 7 (0.24) | 0 (0) |
| Pneumonia | 142 (2.14) | <5 (~1) | 36 (1.25) | 0 (0) |
| Psoriasis | 245 (3.69) | 11 (4.35) | 98 (3.39) | 5 (3.79) |
| Pulmonary embolism | 119 (1.79) | <5 (~1) | 12 (0.42) | 0 (0) |
| Renal impairment | 811 (12.22) | <5 (~1) | 124 (4.3) | 0 (0) |
| Rheumatoid arthritis | 66 (0.99) | <5 (~0) | 30 (1.04) | <5 (~1) |
| Schizophrenia | 21 (0.32) | <5 (~0) | 5 (0.17) | 0 (0) |
| Ulcerative colitis | 29 (0.44) | 0 (0) | 9 (0.31) | <5 (~1) |
| Urinary Tract Infection | 1055 (15.9) | 33 (13.04) | 375 (12.99) | 10 (7.58) |
| Venous thrombosis | 418 (6.3) | 15 (5.93) | 93 (3.22) | <5 (~3) |
| Visual system disorder | 2437 (36.74) | 48 (18.97) | 731 (25.32) | 20 (15.15) |
| Comedications [n (%)] | ||||
| Antidepressants | 3529 (53.2) | 146 (57.71) | 1468 (50.85) | 58 (43.94) |
| Antiepileptics | 1214 (18.3) | 32 (12.65) | 451 (15.62) | 17 (12.88) |
| Antiinflammatory/antirheumatic | 4489 (67.67) | 155 (61.26) | 1930 (66.85) | 76 (57.58) |
| Antineoplastics | 426 (6.42) | <5 (~1) | 122 (4.23) | 5 (3.79) |
| Antipsoriatics | 147 (2.22) | 9 (3.56) | 77 (2.67) | <5 (~3) |
| Antipsychotics | 2020 (30.45) | 77 (30.43) | 785 (27.19) | 37 (28.03) |
| Antithrombotics | 1256 (18.93) | 32 (12.65) | 218 (7.55) | 13 (9.85) |
| Anxiolytics | 2115 (31.88) | 86 (33.99) | 888 (30.76) | 40 (30.3) |
| Beta-blockers | 2055 (30.98) | 68 (26.88) | 725 (25.11) | 34 (25.76) |
| Calcium channel blockers | 2092 (31.53) | 18 (7.11) | 421 (14.58) | 7 (5.3) |
| Diuretics | 2267 (34.17) | 18 (7.11) | 449 (15.55) | 6 (4.55) |
| Drugs for acid-related disorders | 4496 (67.77) | 141 (55.73) | 1707 (59.13) | 67 (50.76) |
| Drugs for diabetes | 660 (9.95) | 13 (5.14) | 134 (4.64) | <5 (~3) |
| Drugs for obstructive airway diseases | 3239 (48.82) | 126 (49.8) | 1350 (46.76) | 60 (45.45) |
| Hypnotics/sedatives | 1686 (25.41) | 77 (30.43) | 778 (26.95) | 39 (29.55) |
| Immunosuppressants | 128 (1.93) | <5 (~1) | 51 (1.77) | <5 (~1) |
| Opioids | 4517 (68.09) | 160 (63.24) | 1798 (62.28) | 79 (59.85) |
| Psychostimulants | <5 (~1) | 0 (0) | <5 (~0) | 0 (0) |
Counts < 5 masked and proportions rounded to nearest 1% in order for patients to remain masked.
IQR, interquartile range; SD, standard deviation.